158 related articles for article (PubMed ID: 38076664)
21. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
22. A historical review of antidepressant effects of ketamine and its enantiomers.
Wei Y; Chang L; Hashimoto K
Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
[TBL] [Abstract][Full Text] [Related]
23. Use of Buprenorphine in treatment of refractory depression-A review of current literature.
Stanciu CN; Glass OM; Penders TM
Asian J Psychiatr; 2017 Apr; 26():94-98. PubMed ID: 28483102
[TBL] [Abstract][Full Text] [Related]
24. Psilocybin in Treatment-Resistant Depression.
Madras BK
N Engl J Med; 2022 Nov; 387(18):1708-1709. PubMed ID: 36322849
[No Abstract] [Full Text] [Related]
25. Lithium counteracts depressive behavior and augments the treatment effect of selective serotonin reuptake inhibitor in treatment-resistant depressed rats.
Kin K; Yasuhara T; Kawauchi S; Kameda M; Hosomoto K; Tomita Y; Umakoshi M; Kuwahara K; Kin I; Kidani N; Morimoto J; Sasaki T; Date I
Brain Res; 2019 Aug; 1717():52-59. PubMed ID: 30953607
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.
Phillips JL; Van Geel A; Burhunduli P; Vasudev D; Batten LA; Norris S; Talbot J; Ortiz A; Owoeye O; Blier P
Int J Neuropsychopharmacol; 2022 Dec; 25(12):992-1002. PubMed ID: 35931041
[TBL] [Abstract][Full Text] [Related]
27. What we Know, What We Do Not Know, and What We May Know Soon About Interventions for Treatment Resistant Depression in Late-Life?
Roose SP; Brown PJ
Am J Geriatr Psychiatry; 2022 May; 30(5):557-559. PubMed ID: 34801381
[No Abstract] [Full Text] [Related]
28. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
Kwak S; Tiller D; Tucker P
J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
[TBL] [Abstract][Full Text] [Related]
29. Drugs for depression.
Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
[No Abstract] [Full Text] [Related]
30. Medications for Treatment-Resistant Depression in Adults.
Arnold MJ; Fulleborn S; Farrell J
Am Fam Physician; 2021 Jan; 103(1):16-18. PubMed ID: 33382567
[No Abstract] [Full Text] [Related]
31. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
Słupski J; Cubała WJ; Górska N; Słupska A; Gałuszko-Węgielnik M
Med Hypotheses; 2020 Nov; 144():110268. PubMed ID: 33254572
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
33. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety.
Goh KK; Chen CH; Chiu YH; Lu ML
J Psychopharmacol; 2019 Jun; 33(6):700-713. PubMed ID: 31081449
[TBL] [Abstract][Full Text] [Related]
34. Treatment-resistant depression with anhedonia: Integrating clinical and preclinical approaches to investigate distinct phenotypes.
Kelly CA; Freeman KB; Schumacher JA
Neurosci Biobehav Rev; 2022 May; 136():104578. PubMed ID: 35176319
[TBL] [Abstract][Full Text] [Related]
35. Treatment-resistant depression: a challenge for future research.
Kasper S
Acta Neuropsychiatr; 2014 Jun; 26(3):131-3. PubMed ID: 25279416
[No Abstract] [Full Text] [Related]
36. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
37. Kynurenine pathway and suicidal ideation in treatment-resistant depression.
Badawy AA
J Psychopharmacol; 2023 Nov; 37(11):1161-1163. PubMed ID: 37941356
[No Abstract] [Full Text] [Related]
38. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
McMakin DL; Olino TM; Porta G; Dietz LJ; Emslie G; Clarke G; Wagner KD; Asarnow JR; Ryan ND; Birmaher B; Shamseddeen W; Mayes T; Kennard B; Spirito A; Keller M; Lynch FL; Dickerson JF; Brent DA
J Am Acad Child Adolesc Psychiatry; 2012 Apr; 51(4):404-11. PubMed ID: 22449646
[TBL] [Abstract][Full Text] [Related]
39. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
40. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
